Track drug policy legislation in real-time and generate personalized advocacy letters to your representatives using AI.
Monitor harm reduction and drug policy legislation
Removes the X-waiver requirement for prescribing buprenorphine, expanding access to medication-assisted treatment for opioid use disorder. Allows any DEA-registered practitioner to prescribe buprenorphine without additional certification.
Appropriates $10 billion annually for evidence-based addiction treatment, harm reduction services, recovery support, and overdose prevention programs. Includes funding for naloxone distribution and peer support specialists.
Removes fentanyl test strips from the definition of drug paraphernalia under federal law, allowing states to legalize their distribution as a harm reduction tool without federal interference.
Authorizes a 5-year federal study of supervised consumption sites in up to 10 cities, examining their impact on overdose deaths, HIV transmission, public safety, and healthcare costs.
Establishes a federal grant program for states to pilot drug decriminalization policies, replacing criminal penalties for personal drug possession with civil citations and mandatory treatment referrals.
This is a test bill